Abdominal Aortic Aneurysm disease
Conditions
Interventions
Product Name: Sinerem
Pharmaceutical Form: Intravenous infusion
Sponsors
University of Edinburgh
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: AAA measuring >40mm in AP diameter on ultrasound scanning Age > 40yrs ( patients younger than this may have a connective tissue disorder and a different aetiology of disease) Considered suitable for standard infra-renal open surgical repair Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Patients who are not deemed to be fit for open surgical repair Patients who for whom endovascular management would be more appropriate Contraindication to MRI scanning Age 250 or eGFR<25) Hepatic dysfunction (Child's grade B or C)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To determine whether magnetic resonance imaging with Sinerem can identify regions of instability (inflammation and neovascularisation) in the wall of abdominal aortic aneurysms.;Secondary Objective: To determine whether areas thought to represent inflammation and neovascularisation on MRI scanning correlate to histologically defined areas of inflammation and neovasculatrisation in tissue samples.;Primary end point(s): Change in relative signal intensity in the wall of the aneurysm on pre- and post-contrast images. | — |
Countries
United Kingdom
Outcome results
None listed